- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
NeoGenomics Reports Revenue of the Fourth Quarter of 2017
NeoGenomics (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2017. As quoted in the press release: Consolidated revenues for the fourth quarter of 2017 were $67.8 million, an increase of 12% over the same period in 2016. After adjusting 2016 results for the divestiture of …
NeoGenomics (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2017.
As quoted in the press release:
Consolidated revenues for the fourth quarter of 2017 were $67.8 million, an increase of 12% over the same period in 2016. After adjusting 2016 results for the divestiture of PathLogic, revenue growth was 15%. Clinical genetic test volume(1) increased by almost 19% year over year. Average revenue per clinical genetic test (“Revenue per Test”) decreased by 8% to $338, primarily due to changes in test mix and reduced reimbursement levels for certain molecular tests.
Click here to read the full press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.